Pressured by patients, FDA reviews ALS drug with modest data | Health & Fitness

Pressured by patients, FDA reviews ALS drug with modest data | Health & Fitness

By MATTHEW PERRONE – AP Health Writer WASHINGTON (AP) — When patients are battling a terminal illness and want access to an experimental drug, how much evidence that it works should regulators require before approval? That’s the question behind many of the Food and Drug Administration’s toughest decisions, including last year’s controversial approval of Aduhelm….

Read More